SCHEMBL4622680

SCHEMBL4622680

CC(NC1CCC(N(C)S(=O)(=O)c2ccc(Nc3nccc(Nc4ccc(F)cc4)n3)cc2)CC1)c1ccccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.43
MAPT P10636 2/20 0.43
MAPK1 P28482 2/20 0.43
RAB9A P51151 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
ALOX12 P18054 1/20 0.43
KMT2A Q03164 1/20 0.43
ACVR1 Q04771 1/20 0.41
MAPK8 P45983 1/20 0.39
PLK1 P53350 2/20 0.39
AURKA O14965 4/20 0.38
AURKB Q96GD4 3/20 0.38
HTR2A P28223 2/20 0.37
HTR1A P08908 1/20 0.37
DRD2 P14416 1/20 0.37
HTR7 P34969 1/20 0.37
HTR2C P28335 1/20 0.37
CDK2 P24941 3/20 0.36
CHRNA7 P36544 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4886446 0.94 MAPK8 (0.40) NPC1MAPTMAPK1RAB9AMEN1
SCHEMBL4624217 0.88 MEN1 (0.45) NPC1MAPTMAPK1RAB9AMEN1
SCHEMBL4623339 0.85 MAPT (0.43) NPC1MAPTMAPK1RAB9AMEN1
SCHEMBL4651482 0.84 MEN1 (0.41) NPC1MAPTMAPK1RAB9AMEN1
SCHEMBL14020249 0.84 MEN1 (0.52) NPC1MAPTMAPK1RAB9AMEN1
SCHEMBL4623169 0.84 MEN1 (0.52) NPC1MAPTMAPK1RAB9AMEN1
SCHEMBL4623094 0.84 MEN1 (0.52) NPC1MAPTMAPK1RAB9AMEN1
SCHEMBL4886277 0.83 MEN1 (0.55) NPC1MAPTMAPK1RAB9AMEN1
SCHEMBL14020253 0.83 MEN1 (0.55) NPC1MAPTMAPK1RAB9AMEN1
SCHEMBL4623749 0.83 MEN1 (0.55) NPC1MAPTMAPK1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed
EP-1904479-A2 NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS Sanofi-Aventis (FR) 2008-04-02 EP disclosed
WO-2007006926-A2 NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2007-01-18 WO disclosed
WO-2007006926-A2 NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors NFKBIA, IKBKB, IKBKE NPC1 3888/4885MAPT 3357/4885MAPK1 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.